VIVEbiotech

vivebiotech.com ↗ ·San Sebastián ·Series A

VIVEbiotech is a GMP contract development and manufacturing organization (CDMO) focused exclusively on lentiviral vectors for cell and gene therapy, serving biotech and pharma clients developing ex vivo (e.g. CAR-T) and in vivo therapies. Founded in 2015 in Donostia-San Sebastián (Basque Country), it is one of the few European CDMOs dedicated solely to lentiviral vectors, has produced 150+ GMP batches, and has developed its own LENTISOMA non-integrative episomal replicative lentiviral vector technology. In December 2024 it received a growth equity investment from US life-sciences PE firm Ampersand Capital Partners to expand capacity, with Jon Alberdi becoming CEO and Stefan Beyer executive chairman; Patricio Massera was named President in July 2025.

Founded

2015

Founders

Total funds raised

€45.6M

SectorsBiotech, Gene Therapy, CDMO / Biomanufacturing, Life Sciences Start-up MapHealthtech & Bio › Biologics manufacturing & CDMO

Suggest a correction

Founders

Gurutz Linazasoro

Founder and Board Member (former CEO/President)

Global models 5

Resilience

United States · resilience.com ↗

A VC-funded biomanufacturing CDMO that makes complex modalities, including viral vectors for cell and gene therapy, under contract for biotech and pharma clients.

~$2BComparable

ElevateBio

United States · www.elevate.bio ↗

Its BaseCamp business offers GMP process development and manufacturing of lentiviral and other viral vectors and cell therapies to outside developers.

~$1.5BComparable

Center for Breakthrough Medicines

United States · www.cbm.com ↗

A cell and gene therapy CDMO (now part of SK pharmteco) that makes lentiviral and AAV vectors and cell therapies for biotech and pharma sponsors.

~$1.1BComparable

Forge Biologics

United States · www.forgebiologics.com ↗

A VC-backed GMP viral-vector CDMO (acquired by Ajinomoto) that makes gene-therapy vectors, mainly AAV, under contract for therapy developers.

~$160MComparable

Genezen

United States · www.genezen.com ↗

A CDMO specialised in lentiviral and retroviral vectors for cell and gene therapy, backed by growth investors, which is the closest match to VIVEbiotech's lentiviral-only model.

undisclosed (Ampersand-backed)Comparable

In the same niche 8 others

See all in the Start-ups Map →

No stage disclosed · €9.9M

53Biologics

Valladolid

No stage disclosed · €7M

+2 more →

Notes: Most funded first

Investors 4

Open as list →

Easo Ventures

easoventures.com

3 rounds, led 1 · 2019–22 Spain

Inveready

inveready.com

3 rounds, led 1 · 2019–22 Spain

Centro para el Desarrollo Tecnológico y la Innovación

www.cdti.es

2 rounds, led 1 · 2020–22 Spain

Ampersand Capital Partners

ampersandcapital.com ↗

Led round 2024 United States

Funding rounds 4

Date	Round	Amount	Lead
2024-12-04	No stage disclosed	€40M	Ampersand Capital Partners
2022-12-15	Series A (estimated)	€1.1M	Lead not disclosed +3 more
2020-07-16	Series A	approximately €1M	CDTI (Innvierte) +2 more
2019-09-09	Series A (estimated)	€3.5M	Inveready Biotech III, Easo Ventures

News

No coverage on record yet.